Alexandra Thiel,Johanna Mrena,Ari Ristimäki
Alexandra Thiel
Gastric cancer remains a leading cause of cancer-related deaths worldwide, although its incidence has been steadily declining during recent decades. Expression of cyclooxygenase-2 (COX-2) is elevated in gastric carcinomas and in their precu...
Claus Schneider,Ambra Pozzi
Claus Schneider
Cancer initiation and progression are multistep events that require cell proliferation, migration, extravasation to the blood or lymphatic vessels, arrest to the metastatic site, and ultimately secondary growth. Tumor cell functions at both...
Jessie W Yester,Etsegenet Tizazu,Kuzhuvelil B Harikumar et al.
Jessie W Yester et al.
Sphingosine-1-phosphate (S1P) was first described as a signaling molecule over 20 years ago. Since then, great strides have been made to reveal its vital roles in vastly different cellular and disease processes. Initially, S1P was considere...
Jocelyn Reader,Dawn Holt,Amy Fulton
Jocelyn Reader
Prostaglandins are lipid compounds that mediate many physiological effects. Prostaglandin E2 (PGE(2)) is the most abundant prostanoid in the human body, and synthesis of PGE(2) is driven by cyclooxygenase enzymes including COX-2. Both eleva...
Michael D Culler,Kjell Oberg,Rudolf Arnold et al.
Michael D Culler et al.
Somatostatin is an important regulator of endocrine and exocrine secretion, affecting the release of many hormones. The effects of somatostatin are mediated through its interaction with one of five somatostatin receptors. Gastroenteropancre...
Daniel Castellano
Daniel Castellano
Lesley A Mathews,Stephanie M Cabarcas,William L Farrar
Lesley A Mathews
The existence of "tumor-initiating cells" (TICs) has been a topic of heated debate for the last few years within the field of cancer biology. Their continuous characterization in a variety of solid tumors has led to an abundance of evidence...
Daniel Castellano,Ramón Salazar,Eric Raymond
Daniel Castellano
In the last 30 years the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased substantially. This could be partly due to improvements in diagnostic imaging, which lead to the incidental diagnosis...
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors [0.03%]
雷帕霉素靶点(mTOR)抑制剂在神经内分泌肿瘤治疗中的应用研究进展
Jaume Capdevila,Ramón Salazar,Irene Halperín et al.
Jaume Capdevila et al.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms that require a multidisciplinary approach for an optimal management. The lack of effectiveness of traditional DNA-damaging agents has led to the exploration of new t...
Kjell Oberg,Daniel Castellano
Kjell Oberg
Neuroendocrine tumors (NETs) consist of a heterogeneous group of malignancies with various clinical presentations and growth rates. The incidence has been estimated to 2.5-5 per 100,000 people per year and prevalence of 35 per 100,000. The ...